Clin Hypertens.
2018 ;24(1):18. 10.1186/s40885-018-0103-7.
Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)
- Affiliations
-
- 1Department of Medical Informatics, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591 Republic of Korea. 01cadiz@hanmail.net.
- 2Department of Endocrinology and Metabolism, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- 3Division of Biomedical Informatics, Systems Biomedical Informatics Research Centre, Seoul National University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul, 110-799 Republic of Korea.
- KMID: 2434272
- DOI: http://doi.org/10.1186/s40885-018-0103-7
Abstract
- BACKGROUND
Randomized controlled trials can be expensive and time-consuming, leading to medical researchers utilizing real-world evidence (RWE) based on already-collected data. We aimed to conduct various RWE studies on angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blocker (ARB), commonly used as first-line therapy for blood pressure, and to develop a multi-center clinical data mart (CDM) of ACEI/ARB for various clinical purposes.
METHODS
Data from electronic medical records of St. Mary's Hospital and the Seoul National University Hospital were collected. We obtained blood and urine test results of patients within the 30"‰days prior to their first prescription of ACEI or ARB, as well as the first date of diagnosis and presence of various chronic and cardiovascular diseases using the International Classification of Diseases-10 classification. One researcher managed data quality and collation for each hospital in order to facilitate patient anonymity. When results were unclear, the responsible investigator for each hospital attempted to resolve ambiguities by direct chart review.
RESULTS
A total of 102,333 patients who were prescribed ACEI or ARB for the first time were included (21,481 ACEI, 80,551 ARB, and 301 both). Our ACEI/ARB-CDM included short-term studies (within 12"‰months) to observe changes in various blood or urinary laboratory test values after the initial prescription of ACEI or ARB and long-term studies to confirm the incidence of various diseases.
CONCLUSION
We established a CDM of RWE for ACEI/ARB prescription, which included various clinical studies. As we accumulate experience in this process, we expect that the use of RWE research will grow and develop.
Keyword
MeSH Terms
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Comparison of Recent Trends in Study Design and Data Analysis Guidelines Using Real-World Data/Real-World Evidence in the United States, Europe, and South Korea and Implication of Development Direction in Future
- Proceed with Caution When Using Real World Data and Real World Evidence
- Case Analysis in Drug Approval by FDA/EMA Using Real-World Data/Real-World Evidence
- Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records
- Should we discontinue angiotensin converting enzyme inhibitor and angiotensin receptor blocker before kidney transplantation?
